214 related articles for article (PubMed ID: 23900238)
21. Interaction of MLL amino terminal sequences with menin is required for transformation.
Caslini C; Yang Z; El-Osta M; Milne TA; Slany RK; Hess JL
Cancer Res; 2007 Aug; 67(15):7275-83. PubMed ID: 17671196
[TBL] [Abstract][Full Text] [Related]
22. DOT1L, the H3K79 methyltransferase, is required for MLL-AF9-mediated leukemogenesis.
Nguyen AT; Taranova O; He J; Zhang Y
Blood; 2011 Jun; 117(25):6912-22. PubMed ID: 21521783
[TBL] [Abstract][Full Text] [Related]
23. Hematopoietic transformation in the absence of MLL1/KMT2A: distinctions in target gene reactivation.
Chen Y; Ernst P
Cell Cycle; 2019 Jul; 18(14):1525-1531. PubMed ID: 31161857
[TBL] [Abstract][Full Text] [Related]
24. Inhibition of histone methyltransferase EZH2 depletes leukemia stem cell of mixed lineage leukemia fusion leukemia through upregulation of p16.
Ueda K; Yoshimi A; Kagoya Y; Nishikawa S; Marquez VE; Nakagawa M; Kurokawa M
Cancer Sci; 2014 May; 105(5):512-9. PubMed ID: 24612037
[TBL] [Abstract][Full Text] [Related]
25. miR-196b directly targets both HOXA9/MEIS1 oncogenes and FAS tumour suppressor in MLL-rearranged leukaemia.
Li Z; Huang H; Chen P; He M; Li Y; Arnovitz S; Jiang X; He C; Hyjek E; Zhang J; Zhang Z; Elkahloun A; Cao D; Shen C; Wunderlich M; Wang Y; Neilly MB; Jin J; Wei M; Lu J; Valk PJM; Delwel R; Lowenberg B; Le Beau MM; Vardiman J; Mulloy JC; Zeleznik-Le NJ; Liu PP; Zhang J; Chen J
Nat Commun; 2012 Feb; 3():688. PubMed ID: 22353710
[TBL] [Abstract][Full Text] [Related]
26. Persistent transactivation by meis1 replaces hox function in myeloid leukemogenesis models: evidence for co-occupancy of meis1-pbx and hox-pbx complexes on promoters of leukemia-associated genes.
Wang GG; Pasillas MP; Kamps MP
Mol Cell Biol; 2006 May; 26(10):3902-16. PubMed ID: 16648484
[TBL] [Abstract][Full Text] [Related]
27. Frat2 mediates the oncogenic activation of Rac by MLL fusions.
Walf-Vorderwülbecke V; de Boer J; Horton SJ; van Amerongen R; Proost N; Berns A; Williams O
Blood; 2012 Dec; 120(24):4819-28. PubMed ID: 23074275
[TBL] [Abstract][Full Text] [Related]
28. A SALL4/MLL/HOXA9 pathway in murine and human myeloid leukemogenesis.
Li A; Yang Y; Gao C; Lu J; Jeong HW; Liu BH; Tang P; Yao X; Neuberg D; Huang G; Tenen DG; Chai L
J Clin Invest; 2013 Oct; 123(10):4195-207. PubMed ID: 24051379
[TBL] [Abstract][Full Text] [Related]
29. MicroRNA-708 is a novel regulator of the Hoxa9 program in myeloid cells.
Schneider E; Pochert N; Ruess C; MacPhee L; Escano L; Miller C; Krowiorz K; Delsing Malmberg E; Heravi-Moussavi A; Lorzadeh A; Ashouri A; Grasedieck S; Sperb N; Kumar Kopparapu P; Iben S; Staffas A; Xiang P; Rösler R; Kanduri M; Larsson E; Fogelstrand L; Döhner H; Döhner K; Wiese S; Hirst M; Keith Humphries R; Palmqvist L; Kuchenbauer F; Rouhi A
Leukemia; 2020 May; 34(5):1253-1265. PubMed ID: 31768018
[TBL] [Abstract][Full Text] [Related]
30. Requirement for CDK6 in MLL-rearranged acute myeloid leukemia.
Placke T; Faber K; Nonami A; Putwain SL; Salih HR; Heidel FH; Krämer A; Root DE; Barbie DA; Krivtsov AV; Armstrong SA; Hahn WC; Huntly BJ; Sykes SM; Milsom MD; Scholl C; Fröhling S
Blood; 2014 Jul; 124(1):13-23. PubMed ID: 24764564
[TBL] [Abstract][Full Text] [Related]
31. Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia.
Dawson MA; Prinjha RK; Dittmann A; Giotopoulos G; Bantscheff M; Chan WI; Robson SC; Chung CW; Hopf C; Savitski MM; Huthmacher C; Gudgin E; Lugo D; Beinke S; Chapman TD; Roberts EJ; Soden PE; Auger KR; Mirguet O; Doehner K; Delwel R; Burnett AK; Jeffrey P; Drewes G; Lee K; Huntly BJ; Kouzarides T
Nature; 2011 Oct; 478(7370):529-33. PubMed ID: 21964340
[TBL] [Abstract][Full Text] [Related]
32. Leukemic transformation of hematopoietic progenitors by MLL-GAS7 in the absence of Hoxa7 or Hoxa9.
So CW; Karsunky H; Wong P; Weissman IL; Cleary ML
Blood; 2004 Apr; 103(8):3192-9. PubMed ID: 15070702
[TBL] [Abstract][Full Text] [Related]
33. The leukemia-associated Mll-Ell oncoprotein induces fibroblast growth factor 2 (Fgf2)-dependent cytokine hypersensitivity in myeloid progenitor cells.
Shah CA; Bei L; Wang H; Platanias LC; Eklund EA
J Biol Chem; 2013 Nov; 288(45):32490-32505. PubMed ID: 24089521
[TBL] [Abstract][Full Text] [Related]
34. MLL is essential for NUP98-HOXA9-induced leukemia.
Shima Y; Yumoto M; Katsumoto T; Kitabayashi I
Leukemia; 2017 Oct; 31(10):2200-2210. PubMed ID: 28210005
[TBL] [Abstract][Full Text] [Related]
35. PBX3 is essential for leukemia stem cell maintenance in MLL-rearranged leukemia.
Guo H; Chu Y; Wang L; Chen X; Chen Y; Cheng H; Zhang L; Zhou Y; Yang FC; Cheng T; Xu M; Zhang X; Zhou J; Yuan W
Int J Cancer; 2017 Jul; 141(2):324-335. PubMed ID: 28411381
[TBL] [Abstract][Full Text] [Related]
36. Hoxa9 and Meis1 are key targets for MLL-ENL-mediated cellular immortalization.
Zeisig BB; Milne T; García-Cuéllar MP; Schreiner S; Martin ME; Fuchs U; Borkhardt A; Chanda SK; Walker J; Soden R; Hess JL; Slany RK
Mol Cell Biol; 2004 Jan; 24(2):617-28. PubMed ID: 14701735
[TBL] [Abstract][Full Text] [Related]
37. A Multiplex CRISPR-Screen Identifies PLA2G4A as Prognostic Marker and Druggable Target for HOXA9 and MEIS1 Dependent AML.
Hassan JJ; Lieske A; Dörpmund N; Klatt D; Hoffmann D; Kleppa MJ; Kustikova OS; Stahlhut M; Schwarzer A; Schambach A; Maetzig T
Int J Mol Sci; 2021 Aug; 22(17):. PubMed ID: 34502319
[No Abstract] [Full Text] [Related]
38. MLL fusion proteins preferentially regulate a subset of wild-type MLL target genes in the leukemic genome.
Wang QF; Wu G; Mi S; He F; Wu J; Dong J; Luo RT; Mattison R; Kaberlein JJ; Prabhakar S; Ji H; Thirman MJ
Blood; 2011 Jun; 117(25):6895-905. PubMed ID: 21518926
[TBL] [Abstract][Full Text] [Related]
39. SIRT2 regulates proliferation and chemotherapy response of MLL-ENL-driven acute myeloid leukemia.
Hao C; Shao X; Song J; Peng M; Lao Y; Mack R; Zhang L; Wei W; Liu N; Wang T; Wu Y; Feng L; Yin L; Wang S; Sun X; Chen S; Zhang J; Li B
Biochem Biophys Res Commun; 2022 Mar; 596():36-42. PubMed ID: 35108652
[TBL] [Abstract][Full Text] [Related]
40. HOX expression patterns identify a common signature for favorable AML.
Andreeff M; Ruvolo V; Gadgil S; Zeng C; Coombes K; Chen W; Kornblau S; Barón AE; Drabkin HA
Leukemia; 2008 Nov; 22(11):2041-7. PubMed ID: 18668134
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
